Oral SERDs in Breast Cancer

CME

A Focus on Oral SERDs in Patients With HR+/HER2- Breast Cancer: Avoiding Early Discontinuation

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: March 27, 2024

Expiration: March 26, 2025

Marla Lipsyc-Sharf
Marla Lipsyc-Sharf, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In your patient with ER-positive/HER2-negative breast cancer with an ESR1 mutation, which strategy would you share with them to mitigate AEs related to elacestrant that may lead to early treatment discontinuation?